Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KYNU | Q16719 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | CTSK | P43235 | 5/20 | 0.56 |
| ▸ | CTSS | P25774 | 4/20 | 0.55 |
| ▸ | CTSL | P07711 | 3/20 | 0.55 |
| ▸ | CTSB | P07858 | 3/20 | 0.55 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.54 |
| ▸ | TACR1 | P25103 | 2/20 | 0.53 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2115471 | 1.00 | KYNU (0.63) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL4346138 | 1.00 | KYNU (0.63) | KYNUALDH1A1ALOX15CTSKCTSS | |
| Hydrochloric Acid SCHEMBL3258256 | 0.99 | KYNU (0.62) | KYNUALDH1A1ALOX15CTSKCTSS | |
| Hydrochloric Acid SCHEMBL3603216 | 0.99 | KYNU (0.62) | KYNUALDH1A1ALOX15CTSKCTSS | |
| Hydrochloric Acid SCHEMBL3603219 | 0.99 | KYNU (0.62) | KYNUALDH1A1ALOX15CTSKCTSS | |
| Trifluoroacetic Acid SCHEMBL5729191 | 0.93 | ALDH1A1 (0.58) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL29521405 | 0.91 | CTSK (0.56) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL29017554 | 0.91 | CTSK (0.56) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL30437751 | 0.91 | CTSK (0.56) | KYNUALDH1A1ALOX15CTSKCTSS | |
| Hydrochloric Acid SCHEMBL6933213 | 0.90 | CTSK (0.54) | KYNUALDH1A1ALOX15CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250241926-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2025-07-31 | — | — | US | disclosed |
| EP-4419207-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2025-07-23 | — | — | EP | disclosed |
| EP-4419207-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| EP-3583096-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2024-03-27 | — | — | EP | disclosed |
| US-11878965-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2024-01-23 | — | — | US | disclosed |
| EP-4267562-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20230257375-A1 | AZETIDINE DERIVATIVES FOR THE TREATMENT OF INTEGRIN ASSOCIATED DISEASES | THE UNIVERSITY OF NOTTINGHAM (GB) | 2023-08-17 | — | — | US | disclosed |
| US-20230257375-A1 | AZETIDINE DERIVATIVES FOR THE TREATMENT OF INTEGRIN ASSOCIATED DISEASES | THE UNIVERSITY OF NOTTINGHAM (GB) | 2023-08-17 | — | — | US | disclosed |
| US-11667673-B2 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2023-06-06 | — | — | US | disclosed |
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| EP-0783518-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO. INC. (US) | 1997-07-16 | — | — | EP | disclosed |
| US-5648368-A | ANTICOAGULANTS | MERCK & CO., INC. (US) | 1997-07-15 | — | — | US | disclosed |
| US-5627202-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 1997-05-06 | — | — | US | disclosed |
| EP-0760658-A1 | COMPOUNDS FOR INHIBITING OSTEOCLAST-MEDIATED BONE RESORPTION | MERCK & CO. INC. (US) | 1997-03-12 | — | — | EP | disclosed |
| WO-1996034010-A2 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-10-31 | — | — | WO | disclosed |
| EP-0673247-A4 | FIBRINOGEN RECEPTOR ANTAGONISTS. | MERCK & CO INC (US) | 1996-05-01 | — | — | EP | disclosed |
| WO-1996010035-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-04-04 | — | — | WO | disclosed |
| WO-1995032710-A1 | COMPOUNDS FOR INHIBITING OSTEOCLAST-MEDIATED BONE RESORPTION | MERCK & CO., INC. (US) | 1995-12-07 | — | — | WO | disclosed |
| EP-0673247-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1995-09-27 | — | — | EP | disclosed |
| WO-1994012181-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1994-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | ITGB1, ITGB2, ITGA2 | KYNU 4869/4885ALDH1A1 399/4885ALOX15 3835/4885 |
| US-20250241926-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | NQO1, VHL, SDHA | KYNU 914/4885ALDH1A1 174/4885ALOX15 664/4885 |
| US-11667673-B2 | Therapeutically active compounds and their methods of use | IDH1, IDH3B, IDH3A | KYNU 3092/4885ALDH1A1 413/4885ALOX15 4668/4885 |
| US-20230257375-A1 | AZETIDINE DERIVATIVES FOR THE TREATMENT OF INTEGRIN ASSOCIATED DISEASES | ITGA6, ITGA1, ITGA2 | KYNU 4397/4885ALDH1A1 579/4885ALOX15 1550/4885 |
| US-11878965-B2 | Inhibitors of peptidylarginine deiminases | PADI4, PADI2, PADI1 | KYNU 2296/4885ALDH1A1 2537/4885ALOX15 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.